Olaparib as maintenance therapy and salvage therapy in recurrent ovarian cancer: The early experience in Taiwan

• Główni autorzy: Chia-Chen Hsu (Autor), Yu-Bin Pan (Autor), Chyong-Huey Lai (Autor), Ting-Chang Chang (Autor), Lan-Yan Yang (Autor), Hung-Hsueh Chou (Autor)
• Format: Książka
• Wydane: Elsevier, 2021-07-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Objective: The first Poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitor, olaparib, was approved by Taiwan Food and Drug Administration in June 2018, which was available under a compassionate use program since 2015. This study aims to report the early experience of the effectiveness and a...